Dr. Matthias Baumann

Biography

He is responsible for Research, Preclinical and Clinical Development, Regulatory Affairs and MOLOGEN’s clinical strategy. Dr. Baumann has more than 26 years of experience in the healthcare industry. He has a strong background in medical sciences and has worked on a broad range of indications and development approaches for chemical and biotechnological compounds. Before joining MOLOGEN, he worked in various management positions with increasing responsibility in the international pharmaceutical, CRO and biotech industries. From 2011 to 2017 he served as Chief Medical Officer and member of the Executive Board of NOXXON Pharma, a Berlin-based biotech company focused on novel cancer therapies. Here he was responsible for the planning and conduct of clinical development programs that brought three candidate molecules to clinical proof of concept. From 2002 to 2010 he served as Chief Scientific Officer and Managing Director of FOCUS Clinical Drug Development, Neuss/Düsseldorf. In this role he was responsible for the design and execution of integrated programs progressing development compounds from the preclinical candidate stage to clinical proof of concept. Prior to working for FOCUS, he served in various research and development roles at Roche and Boehringer Mannheim. After receiving his MD degree from the University of Erlangen, Germany in 1984, Dr. Baumann pursued 5 years of postgraduate training in the fields of oncology and immunology in Germany and the U.S. Dr. Baumann joined Mologen in May 2017 as Chief Medical Officer and Member of the Executive Board. Dr. Baumann currently does not hold any other board memberships.

Research Interest

Clinical Development, Regulatory Affairs